LOGO
LOGO

Deep B-Cell Depletion: The Next Wave In Autoimmune Diseases With Artiva's AlloNK In Focus

By RTTNews Staff Writer   ✉   | Published:   | Follow Us On Google News
happyinvestors 24042026 lt

Shares of Artiva Biotherapeutics Inc. (ARTV) have more than doubled year-to-date, driven by continued progress in its lead AlloNK program.

AlloNK is an off-the-shelf cell therapy made from donor immune cells (NK cells) that are frozen and stored until needed. It helps antibody drugs work better by boosting their ability to drive deep B-cell depletion.

Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe Now
Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Global Economics Weekly Update: April 20 – April 24, 2026

April 24, 2026 15:15 ET
Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.